Therapeutic Antibody & Biosimilar ELISA Kits
Therapeutic Antibody & Biosimilar ELISA Kits
Highly Sensitive Quantitative Kits
Designed for pharmacokinetic (PK), immunogenicity, and ADA studies, our kits support accurate analysis in preclinical and clinical samples across various species
Why Choose ELISA for Drug Monitoring?
Key Features
Our TDM & ADA ELISA Range
Multiple options and formats
Therapeutic mAb ELISA
Screening & quantification
Biosimilar
ELISA
Desgined for QC and biosimilarity assessment
ADA
ELISA
For detection of ADA againts therapeutic mAbs
Custom
ELISA
Development of custom assay upon request
Popular Targets
Free Drug ELISA Kits
Adalimumab Free Drug ELISA Kit (HUMB00071)
€1,199Durvalumab Free drug ELISA Kit (HUMB00058)
€1,119Nivolumab Free Drug ELISA Kit (HUMB00044)
€1,119ADA detection ELISA Kits
Anti-Rituximab ADA ELISA Kit (HUMB00029)
€1,049Anti-Pembrolizumab ADA ELISA Kit (HUMB00047)
€1,049Anti-Infliximab ADA ELISA Kit (HUMB00003)
€1,049
Testimonials & Partners
Supporting Scientists Worldwide
Erika on Trustpilot
Citations
Product | Citation |
|---|---|
Chemical Communications Sensi et al. | |
Cancer Chemotherapy and Pharmacology Gandhi et al. | |
Delivery in 7-10 business days
24 hours on LiveChat & PhD Level support
Competitive ELISA prices
Ensuring reproducible results
cGMP & ISO Certification
High-quality products
Quality is at the core of everything we do.
Manufactured in state-of-the-art facilities, our products meet the highest standards, including current Good Manufacturing Practicies) cGMP, ISO 9001:2015, and ISO 13485:2016 certifications. These ensure consistent quality, customer-focused innovation, and reliable performance in every batch.
ELISA Manufacture Pipeline
Assay Genie ELISA Kits are developed through a rigorous pipeline, from gene synthesis and protein/peptide production to antibody generation and pairing. Each assay undergoes validation to ensure accuracy before ELISA kit production, delivering reliable results for researchers worldwide.
Detection Principle & Protocol
An ELISA protocol involves coating a microplate with a specific capture antibody, adding the sample containing the target analyte, and incubating to allow binding. After washing to remove unbound substances, a detection antibody (linked to an enzyme) is added, followed by a substrate solution that produces a measurable color change. The optical density (OD) is read using a spectrophotometer, with absorbance values correlating to analyte concentration.
What are Therapeutic Antibodies & ADAs?
- Therapeutic mAbs | Designed to bind specific targets and modulate the immune responses or block disease-related pathways.
- Biosimilars | Highly similar versions of approved therapeutic mAbs, while offering a more cost-effective alternative.
- Anti-Drug Antibodies (ADAs) | Immune-generated antibodies that can bind or neutralize therapeutic mAbs, reducing effectiveness.
Why is drug monitoring important ?
- Optimized Dosing | Ensures therapeutic drug concentrations remain within the optimal range for maximum efficacy.
- Reduced Immunogenicity | Prevents overdosing-related side effects and identifies ADA formation that may reduce drug effectiveness.
- Personalized Treatment | Enables dose adjustments based on individual patient responses, improving long-term outcomes
Applications & Data
Therapeutic mAb & Biosimilar ELISA
- Quality Control | ELISA can be used for QC during the development and manufacturing of antibodies
- Biosimilarity assessment | Test similarity between biosimilar and reference product
- PK studies | Assess how mAbs move through the body and help to determine optimal dosing.
- Clinical Development | Monitor the presence of therapeutic & biosimilar mAb in patient samples
Standard Curve Adalimumab ELISA Kit (HUMB00009).
Data from Anti-Adalimumab Free Drug/ADA Dual ELISA (HUMB00012)
Anti-Drug Antibody (ADA) ELISA
- Immunogenicity Assessment | High levels of ADAs may neutralize the therapeutic effects of the drug, rendering it less effective.
- Response Variability | Identify differences in patients response by measuring ADA levels
- Biosimilarity Evaluation | Helps to assess the immunogenicity profile of biosimilars to reference product
- Free vs. Total ADA | Acid dissociation technology breaks antibody complex making ADA detectable
Meet Some of the Genie Team!
At Assay Genie, we're here to help every step of the way. Whether you need guidance choosing the right product, updates on your order, or expert support after your purchase, we've got you covered.
Colm PhD, CEO
Sean PhD, CSO
Shane MSc, Sales Manager
Beatriz, Logistics
David PhD, Partner Manager
Marina PhD, Tech Support
Joe MSc, Sales
Miren PhD, Product Manager
Chris PhD, Development Manager
Zac MSc, Operations Manager
Natalia PhD, Tech Support
José MSc, Development Manager
Frequently asked questions
Customers may place an order in 3 ways. Orders can be made online via pro-forma invoice, on our website, or via email by emailing orders@assaygenie.com. If you wish to send a purchase order, you can find our company under "Assay Genie" or "Reagent Genie Ireland Ltd" on your ordering system. Alternatively, orders may be placed via your local distributor.
Our company can be found under the supplier name "Assay Genie" or "Reagent Genie Ireland Ltd." Still can't find us? Check if we are on your vendor system here. If not, we would be happy to fill out a new supplier form to be registered as a vendor. Alternatively, orders can be placed through your local distributor.
To find out if you can directly order from us or if your order must be made via a distributor click here. Information on your local distributor can be found on this page.
Inquiries can be made online via our 'Contact Us' page. You may also contact us via email at: info@assaygenie.com or orders@assaygenie.com, or by telephone on: +353 15639720. Alternatively, an inquiry can be made via your local distributor.
To create an Assay Genie account, click on 'Register' in the top right corner of the home page. On the registration page fill out the registration details. Once complete, click the 'Create Account' button. To login, click on 'Sign in' in the top right corner of the results page (beside 'Register'). Fill in your email and password and click the 'Sign in' button.
To change the currency of product prices click 'select currency' from the row of options at the top of screen of each web page. Options include: Euro (€), Pound (£), and US Dollar ($).
Once we have received your order a confirmation email will be sent to you. Details such as order number and estimated date of delivery will also be disclosed in this email.
Research related ELISA Kits
Designed to meet your research needs
Current therapeutic antibodies prevent angiogenesis, immune cell evasion and apoptosis inhibition and are used in lung cancer, colon cancer, glioblastomas, solid tumours, breast cancer, colorectal cancer and multiple myeloma.
| Anti-Ramucirumab (Cyramza®) ADA | |
|---|---|
| Product Code | HUMB00023 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Bevacizumab (Avastin®) ADA | |
|---|---|
| Product Code | HUMB00025 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Bevacizumab (Avastin®) ADA | |
|---|---|
| Product Code | HUMB00026 |
| ELISA Type | Antibody screening - Quantitative |
| Anti-Rituximab (Rituxan®, Mabthera®) ADA | |
|---|---|
| Product Code | HUMB00025 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Rituximab (Rituxan®, Mabthera®) ADA | |
|---|---|
| Product Code | HUMB00026 |
| ELISA Type | Antibody screening - Quantitative |
| Anti-Rituximab (Rituxan®, Mabthera®) ADA | |
|---|---|
| Product Code | HUMB00028 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Rituximab (Rituxan®, Mabthera®) ADA | |
|---|---|
| Product Code | HUMB00029 |
| ELISA Type | Antibody screening - Quantitative |
| Anti-Trastuzumab (Herceptin®, Herclon®) ADA | |
|---|---|
| Product Code | HUMB00031 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Trastuzumab (Herceptin®, Herclon®) ADA | |
|---|---|
| Product Code | HUMB00032 |
| ELISA Type | Antibody screening - Quantitative |
| Anti-Cetuximab (Erbitux®) ADA | |
|---|---|
| Product Code | HUMB00034 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Cetuximab (Erbitux®) ADA | |
|---|---|
| Product Code | HUMB00035 |
| ELISA Type | Antibody screening - Quantitative |
| Daratumumab (Darzalex®) ADA | |
|---|---|
| Product Code | HUMB00063 |
| ELISA Type | Antibody screening - Qualitative |
Increasing knowledge of how tumours undergo immune evasion has led to the discovery of drugs called checkpoint inhibitors. These immunotherapies can prevent this override of the immune system, and allow the cancer to be detected and destroyed. These biologics are currently used to treat Merkel Cell Carcinoma (MCC), Melanoma, lung cancer, renal cell carcinoma and head and neck cancer.
| Anti-Avelumab (Bavencio®) ADA | |
|---|---|
| Product Code | HUMB00043 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Nivolumab (Opdivo®) ADA | |
|---|---|
| Product Code | HUMB00045 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Pembrolizumab (Keytruda®) ADA | |
|---|---|
| Product Code | HUMB00047 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Ipilimumab (Yervoy®) ADA | |
|---|---|
| Product Code | HUMB00049 |
| ELISA Type | Antibody screening - Qualitative |
| Atezolizumab (Tecentriq®) ADA | |
|---|---|
| Product Code | HUMB00061 |
| ELISA Type | Antibody screening - Qualitative |
While providing us defence against pathogens, the immune response can also turn inwards and trigger autoimmune disorders. Knowledge of the biochemical pathways involved in inflammation has allowed researchers to target specific agents with therapeutic antibodies/biologics to decrease disease burden, such as arthritis, inflammatory bowel disease, psoriasis, muckle wells disease and many more.
| Anti-Vedolizumab (Entyvio®) ADA Qualitative ELISA Kit | |
|---|---|
| Product Code | HUMB00019 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Ustekinumab (Stelara®) ADA | |
|---|---|
| Product Code | HUMB00021 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Tocilizumab (Actemra®) | |
|---|---|
| Product Code | HUMB00051 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Natalizumab (Tysabri®) ADA | |
|---|---|
| Product Code | HUMB00053 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Canakinumab (Ilaris®) ADA | |
|---|---|
| Product Code | HUMB00057 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Abatacept (Orencia®) ADA | |
|---|---|
| Product Code | HUMB00069 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Secukinumab (Cosentyx® , Verxant®) ADA | |
|---|---|
| Product Code | HUMB00067 |
| ELISA Type | Antibody screening - Qualitative |
Dysregulation in TNFα signalling is a common occurrence in inflammatory disorders. Thus, a range of therapeutic antibodies have been developed to treat a number of pathologies such as; rheumatoid arthritis, Crohn’s disease, ulcerative colitis and psoriasis. Using TDM for these antibodies during treatment is of great benefit in monitoring patient response, optimising dosage and preventing immunogenicity.
| Anti-Infliximab (Remicade®) ADA | |
|---|---|
| Product Code | HUMB00002 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Infliximab (Remicade®) ADA | |
|---|---|
| Product Code | HUMB00003 |
| ELISA Type | Antibody screening - Quantitative |
| Anti-Infliximab (Remicade®) Free Drug/ADA Dual ELISA | |
|---|---|
| Product Code | HUMB00004 |
| ELISA Type | Antibody screening - Free/Total semiquantitative |
| Anti-Infliximab (Remsima®) ADA | |
|---|---|
| Product Code | HUMB00006 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Infliximab (Remsima®) ADA | |
|---|---|
| Product Code | HUMB00007 |
| ELISA Type | Antibody screening - Quantitative |
| Anti-Infliximab (Remsima®) ADA | |
|---|---|
| Product Code | HUMB00008 |
| ELISA Type | Antibody screening - Total semiquantitative |
| Anti-Adalimumab (Humira®) ADA | |
|---|---|
| Product Code | HUMB00010 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Adalimumab (Humira®) ADA | |
|---|---|
| Product Code | HUMB00011 |
| ELISA Type | Antibody screening - Quantitative |
| Anti-Adalimumab (Humira®) Free Drug/ADA Dual ELISA | |
|---|---|
| Product Code | HUMB00012 |
| ELISA Type | Antibody screening - Free/Total semiquantitative |
| Anti-Etanercept (Enbrel®) ADA | |
|---|---|
| Product Code | HUMB00014 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Golimumab (Simponi®) ADA | |
|---|---|
| Product Code | HUMB00016 |
| ELISA Type | Antibody screening - Qualitative |
Macular degeneration is a debilitating illness of the eye that ultimately releases in loss of central vision. Most treatments involve biologics that target VEGF or its receptors to prevent damaging angiogenesis.
| Anti-Bevacizumab (Avastin®) ADA | |
|---|---|
| Product Code | HUMB00025 |
| ELISA Type | Antibody screening - Qualitative |
| Anti-Bevacizumab (Avastin®) ADA | |
|---|---|
| Product Code | HUMB00026 |
| ELISA Type | Antibody screening - Quantitative |
Incidences of allergy and allergic asthma are on the rise worldwide. Treatments for asthma focus on treating the secondary symptoms. Biologics have been created to bind to free IgE in the treatment of asthmatics who are unresponsive to corticosteroids.
| Anti-Omalizumab (Xolair®) ADA | |
|---|---|
| Product Code | HUMB00040 |
| ELISA Type | Antibody screening - Qualitative |
Neutropenia refers to an abnormally low concentration of neutrophils in the blood, and can result in a range of harmful side effects that is commonly seen in patients receiving chemotherapy and HIV. It can be treated with exogenous G-CSF.
Biologics have been developed to combat obesity that present with hyperlypidemia to allow LDL to be removed from the blood.
With age and hormone changes, alterations occur in bone homeostasis that lead to degeneration of bone cells. By targeting RANK-L, it is possible to prevent the growth of osteoclasts that breakdown bone.
| Anti-Denosumab (Prolia®) ADA | |
|---|---|
| Product Code | HUMB00037 |
| ELISA Type | Antibody screening - Qualitative |
Additional Resources
